MXPA03002751A - Fragmentos polipeptidicos del virus de la hepatitis e, composicion de vacuna y equipos de diagnostico que comprenden los mismos. - Google Patents

Fragmentos polipeptidicos del virus de la hepatitis e, composicion de vacuna y equipos de diagnostico que comprenden los mismos.

Info

Publication number
MXPA03002751A
MXPA03002751A MXPA03002751A MXPA03002751A MXPA03002751A MX PA03002751 A MXPA03002751 A MX PA03002751A MX PA03002751 A MXPA03002751 A MX PA03002751A MX PA03002751 A MXPA03002751 A MX PA03002751A MX PA03002751 A MXPA03002751 A MX PA03002751A
Authority
MX
Mexico
Prior art keywords
fragments
polypeptide
hepatitis
virus
hev
Prior art date
Application number
MXPA03002751A
Other languages
English (en)
Spanish (es)
Inventor
Jun Zhang
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of MXPA03002751A publication Critical patent/MXPA03002751A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA03002751A 2000-09-30 2001-09-30 Fragmentos polipeptidicos del virus de la hepatitis e, composicion de vacuna y equipos de diagnostico que comprenden los mismos. MXPA03002751A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00130634A CN1345775A (zh) 2000-09-30 2000-09-30 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
PCT/CN2001/001469 WO2002040681A1 (fr) 2000-09-30 2001-09-30 Fragment polypeptidique du virus de l'hepatite e, composition vaccinale contenant ledit fragment, agent diagnostic et leurs applications

Publications (1)

Publication Number Publication Date
MXPA03002751A true MXPA03002751A (es) 2004-05-04

Family

ID=4594225

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002751A MXPA03002751A (es) 2000-09-30 2001-09-30 Fragmentos polipeptidicos del virus de la hepatitis e, composicion de vacuna y equipos de diagnostico que comprenden los mismos.

Country Status (9)

Country Link
US (3) US7615228B2 (fr)
EP (2) EP1331271B1 (fr)
JP (3) JP5681337B2 (fr)
KR (2) KR101121754B1 (fr)
CN (2) CN101367869B (fr)
AU (1) AU2002220460A1 (fr)
BR (2) BR0114510A (fr)
MX (1) MXPA03002751A (fr)
WO (1) WO2002040681A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367869B (zh) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
US7786264B2 (en) * 2001-11-08 2010-08-31 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
EP2400982B1 (fr) * 2009-02-27 2016-05-11 The Regents of The University of California Système d'administration d'antigène multiple utilisant une particule de type virus de l'hépatite e
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
WO2012028161A1 (fr) * 2010-08-31 2012-03-08 Abb Technology Ag Procédé de débogage de solutions d'installation de fabrication ou de traitement comprenant de multiples sous-systèmes
CN102453748A (zh) * 2010-10-18 2012-05-16 北京雅康博生物科技有限公司 用于荧光定量pcr定量检测的质粒标准品
CN102565410B (zh) * 2012-01-12 2014-08-06 吉林大学 一种梅花鹿朊蛋白免疫学检测方法
ES2900401T3 (es) * 2012-05-09 2022-03-16 Bharat Biotech Int Ltd Combinaciones de vacunas
CN104031144B (zh) * 2013-03-05 2017-08-25 厦门大学 特异结合戊型肝炎病毒3、4型的抗体及其用途
CN104789534B (zh) * 2015-04-10 2017-10-17 浙江中医药大学 一种杂交瘤、单克隆抗体及其用途
FR3044312B1 (fr) * 2015-11-30 2017-12-08 Biomerieux Sa Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
US10512685B2 (en) * 2016-05-25 2019-12-24 Intervet Inc. HEV vaccine
KR101924093B1 (ko) 2017-04-18 2018-11-30 건국대학교 산학협력단 E형 간염 바이러스 유전자형 3 및 4 진단용 프라이머 세트 및 이를 이용한 진단 방법
CN110501505B (zh) * 2018-05-18 2022-06-10 中国兽医药品监察所 小反刍兽疫诊断试剂盒
CN112384530B (zh) * 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位肽
US20210324049A1 (en) * 2018-07-10 2021-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN109942702B (zh) * 2019-03-20 2019-11-08 南京医科大学 一种人鼠嵌合抗HEV全分子IgG及其应用
JP7259622B2 (ja) 2019-07-29 2023-04-18 パナソニックホールディングス株式会社 冷却システム及びその運転方法
CN117730255A (zh) 2021-07-06 2024-03-19 株式会社先端生命科学研究所 E型肝炎病毒感染的检测方法、e型肝炎病毒感染检测用抗原多肽和试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5885768A (en) 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US6214970B1 (en) 1988-06-17 2001-04-10 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US5563032A (en) * 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
EP0736087A1 (fr) 1993-12-22 1996-10-09 Abbott Laboratories Anticorps monoclonaux diriges contre l'antigene orf-2 d'hev et procedes d'utilisation
KR100359526B1 (ko) * 1994-10-03 2003-02-25 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 E형간염파키스탄형균주의재조합단백질및이를이용한진단방법과백신
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE19830896A1 (de) * 1998-07-10 2000-06-08 Mivatec Gmbh Fotoplott-Verfahren zur hochenergetischen Aufzeichnung eines computergespeicherten Rasterbildes auf einen lichtempfindlichen Aufzeichnungsträger
US6045567A (en) * 1999-02-23 2000-04-04 Lifescan Inc. Lancing device causing reduced pain
CA2283538A1 (fr) 1999-09-30 2001-03-30 Mun Hon Ng Nouveau peptide antigenique du hev et methodes
CN101367869B (zh) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗

Also Published As

Publication number Publication date
KR20090088429A (ko) 2009-08-19
CN101367869B (zh) 2012-12-05
EP1331271B1 (fr) 2014-03-19
EP1331271A4 (fr) 2005-04-06
WO2002040681A1 (fr) 2002-05-23
EP2298793A2 (fr) 2011-03-23
US20040052813A1 (en) 2004-03-18
KR101121754B1 (ko) 2012-03-23
KR20030048052A (ko) 2003-06-18
JP5681337B2 (ja) 2015-03-04
US20100150962A1 (en) 2010-06-17
EP1331271A1 (fr) 2003-07-30
BRPI0114510B8 (pt) 2021-05-25
JP2011201881A (ja) 2011-10-13
US7615228B2 (en) 2009-11-10
KR100927221B1 (ko) 2009-11-16
AU2002220460A1 (en) 2002-05-27
US8715695B2 (en) 2014-05-06
JP2014138593A (ja) 2014-07-31
EP2298793A3 (fr) 2011-06-29
BR0114510A (pt) 2004-02-17
JP2004525613A (ja) 2004-08-26
US20100143410A1 (en) 2010-06-10
US8524868B2 (en) 2013-09-03
CN1345775A (zh) 2002-04-24
CN101367869A (zh) 2009-02-18
JP5829830B2 (ja) 2015-12-09
BRPI0114510B1 (pt) 2019-09-03

Similar Documents

Publication Publication Date Title
MXPA03002751A (es) Fragmentos polipeptidicos del virus de la hepatitis e, composicion de vacuna y equipos de diagnostico que comprenden los mismos.
Dietzschold et al. Antigenic structure of rabies virus glycoprotein: ordering and immunological characterization of the large CNBr cleavage fragments
Eisenberg et al. Effect of monoclonal antibodies on limited proteolysis of native glycoprotein gD of herpes simplex virus type 1
KR900701836A (ko) 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
JP2008074867A (ja) ペプチドリガンドを介して結合された複数の免疫原性成分を有するhbvコア抗原粒子
He et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
HU0105379D0 (en) Lawsonia intracellularis vaccine
JP2008505050A (ja) Sarsコロナウイルスsタンパク質およびその使用
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
Robertson et al. Identification of an exposed region of the immunogenic capsid polypeptide VP1 on foot-and-mouth disease virus
EP1253201A3 (fr) Mutants et vaccins du virus de l'anemie infectieuse du poulet et utilisations basees sur les proteines virales vp1, vp2 et vp3 ou des sequences de ce virus assurant leur codage
WO2001021807A8 (fr) Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
Clavijo et al. Development of a competitive ELISA using a truncated E2 recombinant protein as antigen for detection of antibodies to classical swine fever virus
CN101085812A (zh) 一种sars冠状病毒多肽抗原及其应用
CA2338886A1 (fr) Expression et caracterisation d'une proteine d'enveloppe vih-1 associee a une reponse d'anticorps de neutralisation largement reactifs
CN101152570A (zh) 一种猪瘟病毒表位疫苗及其制备方法
Wang et al. Identification of a conserved linear epitope using monoclonal antibody against non-structural protein 3A of foot-and-mouth disease virus with potential for differentiation between infected and vaccinated animals
AU752131B2 (en) Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
CA2491726A1 (fr) Vaccin contre la peritonite infectieuse feline
KR20040041612A (ko) 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도
US7198891B2 (en) Hepatitis C virus peptides and uses thereof
Hua et al. Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus
WO1999009177A3 (fr) Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus
CN102050868B (zh) 一种h1n1猪流感病毒血凝素模拟抗原表位及其应用

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration